TY - DATA T1 - Supplementary Material for: Efficacy and Safety of Topical Pidobenzone 4% as Adjuvant Treatment for Solar Lentigines: Result of a Randomized, Controlled, Clinical Trial PY - 2016/08/11 AU - Campanati A. AU - Giannoni M. AU - Scalise A. AU - De Blasio S. AU - Giuliano A. AU - Giuliodori K. AU - Ganzetti G. AU - Bolletta E. AU - Di Benedetto G. AU - Offidani A. UR - https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Efficacy_and_Safety_of_Topical_Pidobenzone_4_as_Adjuvant_Treatment_for_Solar_Lentigines_Result_of_a_Randomized_Controlled_Clinical_Trial/3569652 DO - 10.6084/m9.figshare.3569652.v1 L4 - https://ndownloader.figshare.com/files/5648853 KW - •Solar lentigines KW - •Combination therapy KW - •Pidobenzone 4% KW - •CO2 laser KW - •Cryotherapy N2 - Background/Objective: This study aims at the evaluation of the efficacy and safety of a combination therapy based on pidobenzone 4% and fractional CO2 laser or cryotherapy in the treatment of solar lentigines and the prevention of eventual posttreatment hyperchromia. Methods: Efficacy was clinically evaluated by grading the pigmentation level with the Skin Tone Color Scale (STCS), and by grading patients' impression through a Visual Analog Scale (VAS). Results: Our study shows that the associated treatment was safe and that it improves the therapeutic results on solar lentigines and prevents postiatrogenic hyperpigmentation compared with physical therapy alone. Conclusion: The combination of cryotherapy and pidobenzone 4% has been found to be the most useful treatment. ER -